17 results on '"Nurhilal Büyükkurt"'
Search Results
2. The clinicopathologic features of multiple primary malignancies in hematology: A cross sectional descriptive study
- Author
-
Mahmut Yeral, Nurhilal Büyükkurt, Can Boga, Aslı Korur, Hakan Ozdogu, Süheyl Asma, Ilknur Kozanoglu, Pelin Aytan, Mutlu Kasar, and Çiğdem Gereklioğlu
- Subjects
Oncology ,medicine.medical_specialty ,lcsh:R5-920 ,Hematology ,business.industry ,medicine.medical_treatment ,metachronous malignancy ,lcsh:R ,lcsh:Medicine ,Retrospective cohort study ,medicine.disease ,Chemotherapy regimen ,Lymphoma ,Radiation therapy ,Thyroid carcinoma ,Internal medicine ,Concomitant ,medicine ,Carcinoma ,hematologic malignancy ,multiple primary malignancy ,synchronous malignancy ,business ,lcsh:Medicine (General) - Abstract
In Turkish literature there are very few studies regarding multiple primary malignancies (MPM). The aim of this study was to analyze the synchronous and the metachronous malignancies that occurred with a hematologic malignancy. All the patients with a hematologic malignancy were enrolled in this cross-sectional, definitive retrospective study. Data were obtained from the medial records. Patients characteristics including demographic features, treatment protocols and overall survival (OS) were recorded. Among 663 patients with a hematologic malignancy, there were 26 patients with MPMs (3.9%). Synchronous malignancies constitute 0.9% and metachronous malignancies were present in 3%. In men diffuse large B-cell lymphoma (DLBCL) and non-small cell lung carcinoma (NSCLC) and in women breast and acute myeloid leukemia were the most common primary and secondary MPMs respectively. The mean cumulative OS of all patients with MPMs was 246.3±33.4 months and the 5 years-OS was 91.3%. In synchronous MPMs the most frequent concomitant tumors were DLBCL and NSCLC. In metachronous tumors the median time interval between first and second malignancies was 69.5 months (range: 31-312). In four patients there were three MPMs. After radiotherapy three patients developed breast, thyroid and skin cancers and in one patient who received radioiodine for the treatment of thyroid carcinoma, DLBCL had developed. The chemotherapeutic agents applied for the primary malignancies consisted of alkylating agents, antimetabolites, anthracyclines, topoisomerase II inhibitors, monoclonal antibodies and mitotic inhibitors. In 75% of the patients with DLBCL who had received R-CHOP chemotherapy regimen, NSCLC had developed during the follow-up period. In conclusion secondary malignancies with hematologic malignancies are not rare and the clinicians should keep the possibility of secondary malignancies in mind and be suspicious during diagnostic evaluations. Warning with regard to the risk of development of secondary malignancies due to the primary treatment should be given to any patient with a hematologic malignancy. [Med-Science 2020; 9(1.000): 94-9]
- Published
- 2020
3. A Comparison of the BEAM and MITO/MEL Conditioning Regimens for Autologous Hematopoietic Stem Cell Transplantation in Hodgkin Lymphoma: An Analysis of Efficiency and Treatment-Related Toxicity
- Author
-
Mahmut Yeral, Nurhilal Büyükkurt, Yener Koc, Ali Ünal, Bulent Eser, Pelin Aytan, Burcu Gungor, Leylagül Kaynar, Can Boga, and Hakan Ozdogu
- Subjects
Oncology ,Melphalan ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Transplantation Conditioning ,Adolescent ,medicine.medical_treatment ,Hematopoietic stem cell transplantation ,Transplantation, Autologous ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Internal medicine ,hemic and lymphatic diseases ,medicine ,Autologous transplantation ,Humans ,neoplasms ,Etoposide ,Retrospective Studies ,Mitoxantrone ,business.industry ,Hematopoietic Stem Cell Transplantation ,Hematology ,Middle Aged ,medicine.disease ,Hodgkin Disease ,carbohydrates (lipids) ,Tolerability ,030220 oncology & carcinogenesis ,Cytarabine ,Female ,business ,Febrile neutropenia ,030215 immunology ,medicine.drug - Abstract
Background Approximately half of patients with relapsed chemosensitive disease achieve robust responses with BEAM (BCNU, etoposide, cytarabine, and melphalan) and autologous stem cell rescue. The scarcity of comparative studies further limits alternative treatment protocols, such as the MITO/MEL (mitoxantrone, melphalan) protocol. Patients and Methods In this retrospective multicenter study, we compared the BEAM and MITO/MEL regimens used before autologous hematopoietic stem cell transplantation (ASCT) in terms of efficacy and side effects in patients with Hodgkin lymphoma. Data met international accreditation rules. Before ASCT, 108 patients received the MITO/MEL, and 34 patients received the BEAM. Results The median follow-up time was 36 months in the MITO/MEL group (range, 3-178) and 23 months in the BEAM group (range, 4-99). After ASCT, the 3-year expected overall survival and disease-free survival rates were 86.1% and 86.1% for the MITO/MEL group and 91.3% and 76.5% for the BEAM group, respectively. Although 50% of patients developed febrile neutropenia attacks in the MITO/MEL group, this rate was 91.1% in the BEAM group. The grade II and higher rates of hepatic, renal, gastrointestinal, and cardiac toxicities were similar in both groups. However, the rate of pulmonary toxicity was determined to be 1.9% in the MITO/MEL group and 29.4% in the BEAM group (P Conclusion The MITO/MEL conditioning regimen seems to be as effective as the BEAM regimen but has better tolerability in terms of pulmonary toxicity and may be used as an alternative option if necessary, depending on the comorbidity status of the patient.
- Published
- 2020
4. Significance of Lymphocyte Count, Monocyte Count, and Lymphocyte-To-Monocyte Ratio in Predicting Molecular Response in Patients with Chronic Myeloid Leukemia: a Single-Centre Experience
- Author
-
Pelin Aytan, Funda Pepedil-Tanrikulu, Nurhilal Büyükkurt, Aslı Korur, Cagla Sariturk, Can Boga, Hakan Ozdogu, and Ilknur Kozanoglu
- Subjects
Adult ,Male ,Oncology ,medicine.medical_specialty ,Adolescent ,Lymphocyte ,Monocytes ,General Biochemistry, Genetics and Molecular Biology ,Leukocyte Count ,Young Adult ,Myelogenous ,Leukemia, Myelogenous, Chronic, BCR-ABL Positive ,hemic and lymphatic diseases ,Internal medicine ,Humans ,Medicine ,Lymphocytes ,Aged ,Retrospective Studies ,Aged, 80 and over ,Hematology ,Reverse Transcriptase Polymerase Chain Reaction ,business.industry ,Monocyte ,Myeloid leukemia ,Retrospective cohort study ,Middle Aged ,Prognosis ,medicine.disease ,Leukemia ,Treatment Outcome ,medicine.anatomical_structure ,Molecular Response ,Female ,business - Abstract
Background Chronic myeloid leukemia (CML) is a disease resulting from BCR-ABL gene fusion. It is possible to monitor treatment by molecular testing for BCR-ABL. The lymphocyte-to-monocyte ratio (LMR) is a commonly used marker associated with prognosis in various neoplasms. This study was performed to evaluate the relevance of absolute lymphocyte count (ALC), absolute monocyte count (AMC), and LMR in predicting molecular response status in patients with chronic phase CML. Methods Samples submitted to our hematology laboratory for BCR-ABL testing between April 2012 and October 2018 were retrospectively reviewed. Concurrent hemogram testing together with the results of quantitative reverse transcriptase-polymerase chain reaction were noted. Data were grouped according to molecular response status and the ALC, AMC, and LMR were compared among patient groups. Results A total of 224 samples from 95 patients were included in the study. Analysis revealed differences between groups when newly diagnosed patients were compared with patients undergoing treatment, regardless of response status. However, analyzing the groups according to molecular response status failed to reveal differences in ALC, AMC, or LMR. Conclusions ALC, AMC, and LMR are not potential biomarkers for predicting molecular response status in patients with chronic phase CML.
- Published
- 2020
5. Allogenic peripheral stem cell transplantation from HLA-matched related donors for adult sickle cell disease: remarkable outcomes from a single-center trial
- Author
-
Çiğdem Gereklioğlu, Cagla Sariturk, Mahmut Yeral, Can Boga, Pelin Aytan, Nurhilal Büyükkurt, Soner Solmaz, Aslı Korur, Hakan Ozdogu, Ilknur Kozanoglu, Süheyl Asma, and Mutlu Kasar
- Subjects
Adult ,Male ,medicine.medical_specialty ,Anemia, Sickle Cell ,Single Center ,Gastroenterology ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Humans ,Transplantation, Homologous ,Medicine ,Retrospective Studies ,Peripheral Blood Stem Cell Transplantation ,Transplantation ,business.industry ,Hematology ,Middle Aged ,Total body irradiation ,medicine.disease ,Tissue Donors ,Fludarabine ,Peripheral stem cell transplantation ,surgical procedures, operative ,Graft-versus-host disease ,030220 oncology & carcinogenesis ,Female ,Stem cell ,business ,Busulfan ,030215 immunology ,medicine.drug - Abstract
Adult patients with sickle cell disease (SCD) are highly susceptible to stem cell transplant complications, including drug toxicity, graft versus host disease (GVHD), and graft rejection due to SCD-related tissue damage, endothelial activation, and inflammation. The scarcity of compatible stem cells for transplantation further limits treatment options, with only 43 cases of adult allogeneic peripheral blood stem cell transplantation (allo-PSCT) from human leukocyte antigen (HLA)-identical sibling donors reported in the international registry for the period 1986-2013. Herein we report remarkable outcomes in a cohort of adult SCD patients who underwent allo-PSCT using a fludarabine (Flu), busulfan (Bu), and anti-T-cell lymphocyte globulin (ATG)-based conditioning regimen in combination with very low dose total body irradiation (TBI), followed by post-transplant cyclophosphamide (Cy) and sirolimus as GVHD prophylaxis. We performed a single-center, retrospective study consisting of 20 consecutive patients (mean age 33.4 years) who underwent allo-PSCT from HLA-matched related donors with a conditioning regimen of Flu 150/Bu 3.2/Cy 29/ATG 30 (Fresenius)/TBI 200 between September 2013 and September 2017. Data were validated by an independent data audit group of the affiliated JACIE-accredited transplantation center. All patients experienced a sustained donor cell engraftment. Full donor chimerism (total cell) occurred within 180 days in all patients. Mean duration of follow-up was 13.8 months (range: 0.3-50 months), with 12 (60%) patients completing 12 months. No non-relapse mortality or graft rejection occurred. Successful treatment was achieved without the presence of graft loss, grade III-IV acute GVHD, extensive chronic GVHD, or other major complications. Allo-PSCT in combination with Flu 150/Bu 3.2/Cy 29/ATG 30(Fresenius)/TBI 200- Cy/Sirolimus therapy yielded encouraging outcomes with no mortality and low incidence of GVHD. Further controlled studies will be necessary to compare transplant protocols and long-term outcomes.
- Published
- 2018
6. Excellent outcomes of allogeneic transplantation from peripheral blood of HLA-matched related donors for adult sickle cell disease with ATLG and posttransplant cyclophosphamide-containing regimen: an update work
- Author
-
Süheyl Asma, Mutlu Kasar, Mahmut Yeral, Çiğdem Gereklioğlu, Aslı Korur, Nurhilal Büyükkurt, Pelin Aytan, Cagla Sariturk, Ilknur Kozanoglu, Can Boga, and Hakan Ozdogu
- Subjects
Oncology ,Adult ,medicine.medical_specialty ,Allogeneic transplantation ,Transplantation Conditioning ,Cyclophosphamide ,Cell ,MEDLINE ,Graft vs Host Disease ,Disease ,Human leukocyte antigen ,Anemia, Sickle Cell ,Internal medicine ,medicine ,Humans ,Transplantation, Homologous ,Transplantation ,business.industry ,Hematopoietic Stem Cell Transplantation ,Hematology ,Peripheral blood ,Tissue Donors ,Regimen ,medicine.anatomical_structure ,business ,medicine.drug - Published
- 2019
7. A Novel Simplified Combination of Monoclonal Antibodies for Flow Cytometric Analysis of Bronchoalveolar Lavage Samples
- Author
-
Ilknur Kozanoglu, Funda Pepedil-Tanrikulu, Nazan Şen, Nurhilal Büyükkurt, and Cagla Sariturk
- Subjects
Lung Diseases ,Male ,medicine.medical_specialty ,Pathology ,Lung Neoplasms ,Neutrophils ,medicine.drug_class ,CD14 ,CD16 ,Monoclonal antibody ,Sensitivity and Specificity ,General Biochemistry, Genetics and Molecular Biology ,Flow cytometry ,Leukocyte Count ,Internal medicine ,Leukocytes ,medicine ,Humans ,Retrospective Studies ,Microscopy ,Pathology, Clinical ,Lung ,Hematology ,medicine.diagnostic_test ,biology ,business.industry ,Macrophages ,Antibodies, Monoclonal ,Reproducibility of Results ,Middle Aged ,respiratory system ,Flow Cytometry ,Eosinophils ,medicine.anatomical_structure ,Bronchoalveolar lavage ,biology.protein ,Feasibility Studies ,Female ,Antibody ,business ,Bronchoalveolar Lavage Fluid - Abstract
Background The profile of leukocytes in bronchoalveolar lavage (BAL) fluid provides important information for diagnosing various lung diseases. A differential cell count of BAL is conventionally performed by evaluating centrifuged samples under a light microscope and enumerating the stained cells. Another rarely used method to identify BAL leukocytes is flow cytometry (FCM). However, there are no guidelines for standardizing this method and related literature is limited. This study aimed to evaluate the accuracy of FCM for identifying BAL leukocytes. Methods The BAL samples accepted to the hematology laboratory between 2014 - 2018 were retrospectively evaluated via light microscopy (LM) by a hematologist; while flow cytometric analyses with a monoclonal antibody panel composed of CD45/CD14/CD16 were noted by another doctor. The percentages of macrophages, lymphocytes, neutrophils and eosinophils determined by both methods were recorded for analysis. Correlations between the results from LM and FCM were investigated. In addition, compatibility between LM and FCM for denoting pathological values for each cell type was checked. Results Among 140 reviewed BAL samples, 76 were included for further analysis. Comparisons revealed strong correlations between FCM and LM for identifying macrophages, lymphocytes, neutrophils, and eosinophils. In addition, regarding the normal cutoff values for each leukocyte type, FCM and LM were similar in the identification of pathological changes of all cell types except eosinophils. Conclusions Flow cytometry was found to be feasible for use instead of LM and might become a more widely used technique to analyze BAL fluid in the future.
- Published
- 2019
8. QTc prolongation during peripheral stem cell apheresis in healthy volunteers
- Author
-
Mahmut Yeral, Çiğdem Gereklioğlu, Ilknur Kozanoglu, Can Boga, Nurhilal Büyükkurt, Fatih Kandemir, Süheyl Asma, Aslı Korur, Hakan Ozdogu, Cagla Sariturk, and Soner Solmaz
- Subjects
medicine.diagnostic_test ,business.industry ,Physical examination ,Hematology ,General Medicine ,Leukapheresis ,030204 cardiovascular system & hematology ,QT interval ,Sudden death ,Transplantation ,03 medical and health sciences ,0302 clinical medicine ,Apheresis ,Anesthesia ,medicine ,cardiovascular diseases ,Prospective cohort study ,business ,Electrocardiography ,030215 immunology - Abstract
Background and aim Today, voluntary donation of peripheral blood stem cells by healthy donors for allogeneic hemopoietic cell transplantation is common worldwide. Such donations are associated with small but measurable risks of morbidity and mortality. Most complications are associated with citrate infusion during cell collection. We studied the effects of citrate infusion on the QTc and other vital parameters during and after peripheral stem cell apheresis in volunteers. Method To ensure that donors were healthy, screening included taking a detailed medical history, physical examination, and laboratory measurements of plasma calcium and magnesium. Corrected QT (QTc) values were assessed using a 12-lead electrocardiographic platform that derived QTc values automatically. Results In all, 141 apheresis procedures were performed. The mean QTc values at baseline, at 2 and 4 h during the procedure, and at 30 min after the procedure, were 347.6 ± 59.5, 349.9 ± 52.8, 391.8 ± 54.0, and 404.8 ± 59.2 ms, respectively. The baseline and 2 h QTcs did not differ significantly, but the baseline QTc did differ significantly from the 4 h and 30 min after the procedure values. The plasma levels of calcium and magnesium did not significantly differ before and after the procedure. Conclusion QTc prolongation may develop during leukopheresis, particularly if the procedure takes more than 2 h. Thus, to enhance donor safety, QTc measurement should be standard for all donors. In addition, any family history of sudden death should be noted, to prevent the development of possible fatal arrhythmia in susceptible donors.
- Published
- 2016
9. Comparative efficacy in red blood cell exchange transfusions with different apheresis machines in patients with sickle cell disease
- Author
-
Aslı Korur, Mahmut Yeral, Nurhilal Büyükkurt, Can Boga, Hakan Ozdogu, Fatih Kandemir, Çiğdem Gereklioğlu, Cagla Sariturk, Soner Solmaz, Ilknur Kozanoglu, and Süheyl Asma
- Subjects
medicine.medical_specialty ,Hematology ,business.industry ,Cell ,Disease ,030204 cardiovascular system & hematology ,Gastroenterology ,03 medical and health sciences ,Red blood cell ,0302 clinical medicine ,medicine.anatomical_structure ,Apheresis ,Cobe spectra ,Internal medicine ,medicine ,In patient ,Original Article ,Foot ulcers ,business ,030215 immunology - Abstract
The purpose of this study is to compare the efficacy and side effects of two red blood cell exchange (RBCX) transfusion systems in sickle cell disease (SCD). The data is collected retrospectively from the January 2010 to March 2015. 447 RBCX transfusions were performed to 165 patients. Side effects, clinical and technical efficacy were compared in between procedures with Cobe Spectra (CS) and Spectra Optia (SO) systems. Furthermore a subgroup analyses was performed for 40 patients who had RBCX transfusions with both system at least two times. Vasoocclusive crises, preoperative period and foot ulcers (49.6, 13, and 15.2% respectively) were the common indications of RBCX transfusion. While the levels of post-RBCX HbS and the actual fraction of cells remaining (FCRa) were found significantly higher in the SO compared to CS system (p = 0.018 and p = 0.016 respectively), the rate of targeted hemoglobin S (HbS) levels (
- Published
- 2017
10. Demodicidosis Accompanying Acute Cutaneous Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation
- Author
-
Mahmut Yeral, Nurhilal Büyükkurt, Ilknur Kozanoglu, Çiğdem Gereklioğlu, Pelin Aytan, Nazım Emrah Koçer, Can Boga, and Hakan Ozdogu
- Subjects
lcsh:Internal medicine ,Pathology ,medicine.medical_specialty ,Acute graft-versus-host disease ,lcsh:RC633-647.5 ,business.industry ,lcsh:Diseases of the blood and blood-forming organs ,Hematology ,030230 surgery ,Cutaneous graft-versus-host disease ,Demodex folliculitis ,Post transplant ,Transplantation ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Post-transplantation ,Acute graft versus host disease ,Medicine ,Stem cell ,lcsh:RC31-1245 ,business ,Letter to the Editor - Published
- 2018
11. Survival of AML Patients Relapsing after Hematopoetic Stem Cell Transplantation: A Single Center Experience
- Author
-
Mutlu Kasar, Çiğdem Gereklioğlu, Ilknur Kozanoglu, Pelin Aytan, Soner Solmaz, Funda Pepedil Tanrikulu, Aslı Korur, Süheyl Asma, Can Boga, Hakan Ozdogu, Mahmut Yeral, and Nurhilal Büyükkurt
- Subjects
medicine.medical_specialty ,education.field_of_study ,business.industry ,medicine.medical_treatment ,Immunology ,Population ,Salvage therapy ,Cell Biology ,Hematology ,Hematopoietic stem cell transplantation ,medicine.disease ,Biochemistry ,Minimal residual disease ,Gastroenterology ,Transplantation ,Graft-versus-host disease ,Internal medicine ,Medicine ,business ,education ,Survival rate ,Progressive disease - Abstract
Although it is presumed to be a curative strategy for intermediate and high risk acute myeloid leukemia (AML), many patients relapse after allogeneic hematopoietic stem cell transplantation. This prompt us to examine the ways to improve the outcomes. We retrospectively evaluated 76 AML patients who were transplanted between 2007-2017 years in our clinic. We tried to identify the factors associated with posttransplant relapse, postrelapse survival and if there was a survival benefit of pretransplant consolidation and minimal residual disease (MRD) negativity. We examined the effect of the acute-chronic graft versus host disease (GVHD) and salvage therapy after the posttransplant relapses. The mean age of the patients was 44.6±1.21 years (ranges 21-67). 42.1% were females and 57.9% were males. 43.3% of the patients were in complete remission (CR) MRD positive state before the transplantation whereas 35.5% were in CR MRD negative and 3.9% were in progressive disease state. In 13 patients who were in CR state, the MRD status were not known. 11 (14.5%) patients were considered as in favorable risk, 52 (68.4%) in intermediate risk and 13 (17.1%) in unfavorable risk with respect to cytogenetic analysis before the transplantation. The donors were HLA compatible relatives (77.6%), HLA compatible non-relatives (10.5%), haploidentical people (9.2%), one HLA incompatible relative (1.3%) and one HLA incompatible nonrelative (1.3%). 74 bone marrow transplantations (97.4%) were allogeneic and the remaining two (2.6%) were autologous. Myeloablative conditioning regimen was applied to 57 patients (75%) and 19 patients got (25%) reduced intensity conditioning regimen. GVHD developed in 51.3% after transplantation and 61.5% of these were chronic extensive. Relapse occurred in 27 patients (35.5%), hematological relapse being the most common (31.6%). The median time for the development of relapse was found to be 5.5 months (range: 1.5-37). The overall probability for the development of a relapse was found to be 48.7% (95% CI: 40.9-56.5)(Figure1A). 23 patients (30.3%) died during the study period with a median survival of 9.6 months (range: 1.6-45). In the studied population the overall survival probability was found to be 52.8% (95% CI: 45.4 - 60.2) [Figure 1B]. 36.4%, 28.8% and 30.8% of the patients with favorable, intermediate and unfavorable cytogenetic status died respectively during the study period. The comparison of the survival probability of the patients with favorable, intermediate and unfavorable cytogenetic status was depicted in Figure 2. The overall survival probability of the patients with favorable, intermediate and unfavorable cytogenetic status were 46.6% (95% CI: 26.2-66.9), 54.6% (95 % CI: 45.9 - 63.2) and 36.9 % (95% CI: 25.4 - 48.5) respectively (p=0.807). MRD status of 60 patients were known. At the end of the study period 75.8% of the CR MRD positive and 70.4% of the CR MRD negative patients remained alive. The comparison of the survival of patients in CR with respect to MRD status is shown in Figure 3. The overall survival probability of CR MRD positive patients was 56.3 % (95% CI: 45.3 - 67.3) and this rate was 52.5 % (95% CI: 40.8 - 64.3) in MRD negative patients (p=0.770) [Figure 3]. Patients who developed GVHD had similar overall survival probability with the patients who did not developed the disease; 47.0% vs 57.2%, p=0.115 (Figure 4A). Even the patients with chronic extensive GVHD had similar overall survival rates with the patients who had none or acute GVHD; 49.3 % vs 58.2%, p=0.27 (Figure 4B). 66.7% of the patients with a progressive disease before the transplantation died during the study period and this rate was 27.1% in the patients with CR (p=0.005). In conclusion the overall survival rate of the transplanted AML patients was 52.8% in the study group. The overall survival did not seem to be affected by pre-transplant MRD status, cytogenetic risk factors and administration of consolidation therapy. The only patients who had significantly worse results were the ones who had progressive disease before the transplantation. From this point it would be logical to make transplantation whenever the patient is in first CR regardless of the MRD status and a matched donor is found so that the toxic effects of the consolidation chemotherapy may be prevented. Disclosures No relevant conflicts of interest to declare.
- Published
- 2018
12. Survival Outcomes of Young Multiple Myeloma Patients: A Single Center Experience
- Author
-
Can Boga, Süheyl Asma, Hakan Ozdogu, Mahmut Yeral, Mutlu Kasar, Pelin Aytan, Nurhilal Büyükkurt, Aslı Korur, Funda Pepedil Tanrikulu, Çiğdem Gereklioğlu, Ilknur Kozanoglu, and Soner Solmaz
- Subjects
Chemotherapy ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Incidence (epidemiology) ,Immunology ,Complete remission ,Cell Biology ,Hematology ,medicine.disease ,Single Center ,Biochemistry ,Chemotherapy regimen ,Transplantation ,Internal medicine ,medicine ,business ,Kappa ,Multiple myeloma - Abstract
Multiple myeloma (MM) is a disease of the elderly. It shows rapidly increasing incidence with increased age. Although MM is rare in young people, patients diagnosed before the age of 50 years account for 10% of the overall incidence and approximately 2% are diagnosed before 40 years of age. The aim of the study was to assess the clinical results of the young MM patients diagnosed at the age of ≤45 years. All the MM patients who were ≤45 years old at the time of diagnosis and who were admitted to our clinic between January 2004 and December 2017 were retrospectively assessed. There was a total of 31 patients and 14 (45.2%) of them were females and 17 (54.8%) of them were males. The mean age was 40.4±3.8 years. The most frequent myeloma types were Ig G Kappa (n:12, 38.7%) and Kappa light chain (n: 10, 32.3%). The remaining types were Ig A lambda (n:4, 12.9%), Ig G lambda (n:2, 6.5%), Lambda light chain (n: 2, 6.5%) and non-secretory myeloma (n:1, 3.2%). Before transplantation 12 patients (38.7%) were in complete remission, 11 patients (35.5%) were in very good partial remission, 4 patients (12.9%) were in partial remission state and 4 patients (12.9%) had refractory disease. VAD + VCD protocol was given to 12 (38.7%) patients. 6 (19.8%) patients had VCD, 3 (9.7%) got VCD + VRD, 2 (6.5%) got VAD and 8 (25.8%) got other chemotherapy protocols. Transplantation was done in 26 patients (83.9%). Overall 9 patients (29%) died during the study period. Second or tandem transplantation was performed to 10 patients and 30% (n:3) of these re-transplanted patients died. The overall survival for these patients was estimated to be 70% (95% CI: 64.2-75.8). In conclusion MM in patients younger than 45 years is rare. In these patients Ig G Kappa and Kappa Light chain types are the most frequent types. Heterogeneous of individual patients may exist within these young myeloma patients. For those who are expected to show a poor response to current treatments despite their young age, the efficacy of an alternative therapeutic strategy such as front line allo-HSTC should be further investigated. Disclosures No relevant conflicts of interest to declare.
- Published
- 2018
13. Effectiveness of Visual Methods in Information Procedures for Stem Cell Recipients and Donors
- Author
-
Cagla Sariturk, Can Boga, Hakan Ozdogu, Ilknur Kozanoglu, Songul Tepebasi, Mahmut Yeral, Süheyl Asma, Nurhilal Büyükkurt, Aslı Korur, Çiğdem Gereklioğlu, and Soner Solmaz
- Subjects
Adult ,Male ,Audiovisual method ,lcsh:Internal medicine ,medicine.medical_specialty ,Adolescent ,Bone marrow transplantation ,Video Recording ,Affect (psychology) ,Hematopoietic stem cell ,Session (web analytics) ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Informed consent ,Surveys and Questionnaires ,Medicine ,Humans ,Prospective randomized study ,Prospective Studies ,lcsh:RC31-1245 ,Aged ,Informed Consent ,lcsh:RC633-647.5 ,business.industry ,Hematopoietic Stem Cell Transplantation ,lcsh:Diseases of the blood and blood-forming organs ,Hematology ,Middle Aged ,Tissue Donors ,Transplant Recipients ,Test (assessment) ,Transplantation ,030220 oncology & carcinogenesis ,Physical therapy ,Anxiety ,Female ,medicine.symptom ,business ,Donor ,030215 immunology ,Visual methods ,Stem Cell Transplantation ,Research Article - Abstract
Obtaining informed consent from hematopoietic stem cell recipients and donors is a critical step in the transplantation process. Anxiety may affect their understanding of the provided information. However, use of audiovisual methods may facilitate understanding. In this prospective randomized study, we investigated the effectiveness of using an audiovisual method of providing information to patients and donors in combination with the standard model.A 10-min informational animation was prepared for this purpose. In total, 82 participants were randomly assigned to two groups: group 1 received the additional audiovisual information and group 2 received standard information. A 20-item questionnaire was administered to participants at the end of the informational session.A reliability test and factor analysis showed that the questionnaire was reliable and valid. For all participants, the mean overall satisfaction score was 184.8±19.8 (maximum possible score of 200). However, for satisfaction with information about written informed consent, group 1 scored significantly higher than group 2 (p=0.039). Satisfaction level was not affected by age, education level, or differences between the physicians conducting the informative session.This study shows that using audiovisual tools may contribute to a better understanding of the informed consent procedure and potential risks of stem cell transplantation.Amaç: Hematopoietik kök hücre alıcıları ve donörlerden bilgilendirilmiş onam alınması, nakil sürecinin en önemli basamağıdır. Görsel yöntemlerden yararlanılması anlamayı kolaylaştırabilir. Bu prospektif randomize çalışmada sözel ve yazılı bilgilendirmeye ilave olarak audiovizüel yöntem kullanılmasının standart yönteme göre etkinliğinin araştırılması amaçlanmıştır. Gereç ve Yöntemler: On dakikalık kısa bir bilgilendirme animasyonu hazırlatıldı. Toplam 82 katılımcı rastgele 2 gruba ayrıldı: Grup 1 (görsel bilgilendirme yönteminin ilave edildiği grup) ve grup 2 (standart yöntem uygulanan grup). Bilgilendirme işlemi sonunda katılımcılara 20 soruluk bir anket uygulandı. Ayrıca, yeni yöntemin sonuçlarının kişiler arası farklılıktan etkilenip etkilenmediği test edildi. Bulgular: Güvenirlik testi ve faktör analizi anketin güvenilir ve geçerli olduğunu gösterdi. Tüm olgular için genel memnuniyet ortalama değeri 200 üzerinden 184,8±19,8 olarak bulundu. Yazılı bilgilendirilmiş onam form memnuniyeti ortalama puanları yönünden grup 1’deki olguların memnuniyetleri grup 2’ye oranla anlamlı olarak daha yüksek olduğu saptandı (p=0,039). Sözel olarak bilgi veren doktor ve bilgilendirme animasyonu memnuniyeti bakımından gruplar arasında fark saptanmadı. Olguların memnuniyet seviyesi yaş, eğitim durumu ve bilgilendiren kişiler arası farklılıktan etkilenmedi. Sonuç: Bu çalışma, görsel yöntemlerin kullanılmasının işlem ve muhtemel risklerinin daha iyi anlaşılmasına katkı sağlayabileceğini göstermektedir. Anahtar Sözcükler: Hematopoietik kök hücre, Donör, Bilgilendirilmiş onam, Audovizuel yöntem, Kemik iliği nakli.
- Published
- 2016
14. ANORECTAL COMPLICATIONS DURING NEUTROPENIC PERIOD IN PATIENTS WITH HEMATOLOGIC DISEASES
- Author
-
Çiğdem Gereklioğlu, Süheyl Asma, Mutlu Kasar, Soner Solmaz, Mahmut Yeral, Aslı Korur, Nurhilal Büyükkurt, Ilknur Kozanoglu, Can Boga, and Hakan Ozdogu
- Subjects
medicine.medical_specialty ,Disease ,Neutropenia ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,In patient ,business.industry ,lcsh:RC633-647.5 ,Mortality rate ,Hematology ,lcsh:Diseases of the blood and blood-forming organs ,medicine.disease ,Surgery ,Leukemia ,leukemia, neutropenia, anorectal complication, perianal infection ,Infectious Diseases ,Hematologic disease ,INFECTIONS ,030220 oncology & carcinogenesis ,Absolute neutrophil count ,Original Article ,030211 gastroenterology & hepatology ,business ,Complication - Abstract
Background: Neutropenic patients are susceptible to any anorectal disease, and symptomatic anorectal disease afflicts 2-32% of oncology patients. Perianal infections are the most feared complication, considering the lack of natural defense against infectious microorganisms. When septic complications develop, the anorectal disease is potentially fatal, especially in neutropenic patients in whom mortality rates range between 11-57%. Although anorectal diseases are a frequent complication with potentially fatal outcomes among patients with hematologic diseases, sufficient data are not available in the literature. In this study, we aimed to investigate the anorectal complications developing during the neutropenic period in patients with hematologic diseases. Methods: A total of 79 patients whose neutropenic period (absolute neutrophil count < 500/mcL) continued for 7 days, or longer were included in the study. Results: A total of 34 patients out of 79 (43%) were detected to develop anorectal complications, of them 6 (7.6%) developed an anorectal infection. The patients were characterized according to the hematological disease and its status (active or not), the type of treatment and the presence of a history of an anorectal pathology before the onset of the hematologic disease. Nineteen (24.1%) patients had the history of anorectal disturbances before diagnosis of the hematologic disease, and recurrence of an anorectal pathology was found in 14 out of 19 patients(73.7%). In addition, the overall mortality rate was higher among the patients who developed anorectal complications compared to another group (41.2% vs. 22.2%, p= 0.059). Conclusion: Anorectal pathology is a common complication with high recurrence rate in neutropenic patients. Perianal infections are important as they can cause life-threatening outcomes although they are relatively rare among all anorectal complications. Therefore perianal signs and symptoms should be meticulously evaluated concerning early diagnosis and treatment.
- Published
- 2016
15. East Mediterranean region sickle cell disease mortality trial: retrospective multicenter cohort analysis of 735 patients
- Author
-
Çiğdem Gereklioğlu, Cagla Sariturk, Selma Unal, Süheyl Asma, Can Boga, Hakan Ozdogu, Mutlu Kasar, Pelin Karacaoğlu, Aslı Korur, Demircan Ozbalci, Mahmut Yeral, Nurhilal Büyükkurt, Hasan Kaya, Soner Solmaz, Emel Gürkan, and Çukurova Üniversitesi
- Subjects
Adult ,Male ,Pediatrics ,medicine.medical_specialty ,Adolescent ,Turkey ,Thalassemia ,Population ,Anemia, Sickle Cell ,Cohort Studies ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,hemic and lymphatic diseases ,medicine ,Humans ,Mortality ,education ,Retrospective Studies ,education.field_of_study ,Univariate analysis ,Mediterranean Region ,business.industry ,Painful crisis ,Sickle cell disease ,Retrospective cohort study ,Hematology ,General Medicine ,Middle Aged ,medicine.disease ,Acute chest syndrome ,Cross-Sectional Studies ,Hemoglobinopathy ,030220 oncology & carcinogenesis ,Female ,Transfusion therapy ,business ,030215 immunology ,Cohort study - Abstract
PubMedID: 27068408 Sickle cell disease (SCD), one of the most common genetic disorders worldwide, is characterized by hemolytic anemia and tissue damage from the rigid red blood cells. Although hydroxyurea and transfusion therapy are administered to treat the accompanying tissue injury, whether either one prolongs the lifespan of patients with SCD is unknown. SCD-related mortality data are available, but there are few studies on mortality-related factors based on evaluations of surviving patients. In addition, ethnic variability in patient registries has complicated detailed analyses. The aim of this study was to investigate mortality and mortality-related factors among an ethnically homogeneous population of patients with SCD. The 735 patients (102 children and 633 adults) included in this retrospective cohort study were of Eti-Turk origin and selected from 1367 patients seen at 5 regional hospitals. A central population management system was used to control for records of patient mortality. Data reliability was checked by a data supervision group. Mortality-related factors and predictors were identified in univariate and multivariate analyses using a Cox regression model with stepwise forward selection. The study group included patients with homozygous hemoglobin S (Hgb S) disease (67 %), Hb S-ß0 thalassemia (17 %), Hgb S-ß+ thalassemia (15 %), and Hb S-? thalassemia (1 %). They were followed for a median of 66 ± 44 (3–148) months. Overall mortality at 5 years was 6.1 %. Of the 45 patients who died, 44 (6 %) were adults and 1 (0.1 %) was a child. The mean age at death was 34.1 ± 10 (18–54) years for males, 40.1 ± 15 (17–64) years for females, and 36.6 ± 13 (17–64) years overall. Hydroxyurea was found to have a notable positive effect on mortality (p = 0.009). Mortality was also significantly related to hypertension and renal damage in a univariate analysis (p = 0.015 and p = 0.000, respectively). Acute chest syndrome, splenic sequestration, and prolonged painful-crisis-related multiorgan failure were the most common causes of mortality. In a multivariate analysis of laboratory values, only an elevated white blood cell count was related to mortality (p = 0.009). These data show that despite recent progress in the treatment of SCD, disease-related factors continue to result in mortality in young adult patients. Our results highlight the importance of evaluating curative treatment options for patients who have an appropriate stem cell donor in addition to improving patient care and patient education. © 2016, Springer-Verlag Berlin Heidelberg.
- Published
- 2016
16. The Effect of FcγRIIIA Gene Polymorphism on the Treatment of Diffuse Large B-cell Non-Hodgkin Lymphoma: A Multicenter Prospective Observational Study
- Author
-
Mehmet Ali Özcan, Hayri Özsan, Bülent Ündar, Bahriye Payzin, Nurhilal Büyükkurt, Sunay Tunali, Fatih Demirkan, Ülkü Ergene, and Özden Pişkin
- Subjects
Male ,Turkey ,Bioinformatics ,Gastroenterology ,Severity of Illness Index ,Gene Frequency ,Prednisone ,Antineoplastic Combined Chemotherapy Protocols ,Prospective Studies ,Aged, 80 and over ,lcsh:Diseases of the blood and blood-forming organs ,Hematology ,Diffuse large B-cell lymphoma ,Middle Aged ,Survival Rate ,RIIIA ,Treatment Outcome ,FcγRIIIA ,Vincristine ,Rituximab ,Female ,Lymphoma, Large B-Cell, Diffuse ,medicine.drug ,Research Article ,Adult ,lcsh:Internal medicine ,medicine.medical_specialty ,Genotype ,Single-nucleotide polymorphism ,Real-Time Polymerase Chain Reaction ,Polymorphism, Single Nucleotide ,Young Adult ,Internal medicine ,medicine ,Humans ,Allele ,lcsh:RC31-1245 ,Cyclophosphamide ,Alleles ,Aged ,lcsh:RC633-647.5 ,business.industry ,Receptors, IgG ,Fcγ ,medicine.disease ,Lymphoma ,Doxorubicin ,Fc gamma RIIIA ,Gene polymorphism ,business ,Follow-Up Studies - Abstract
The curative treatment approach for diffuse large B-cell lymphoma (DLBCL) is controversial even in the rituximab (R) era. The aim of this study was to examine the FcγRIIIA gene polymorphism distribution of DLBCL patients who had been treated with R-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy. Furthermore, we investigated the impact of FcγRIIIA gene polymorphism on the overall response rate (ORR) and overall survival (OS).Patients from 3 centers in the Aegean region of Turkey who had newly diagnosed CD20-positive DLBCL were enrolled in the study. The single nucleotide polymorphisms of the FcγRIIIA gene were analyzed by real time-PCR. The response to treatment was determined in the middle and at the end of the protocol. During 2 years of follow-up, the patients were clinically and radiologically evaluated for disease status every 3 months.Thirty-six patients were included in the study and the distributions of F/F, V/F, and V/V types of alleles of FcγRIIIA were 25%, 50%, and 25%, respectively. Twenty-seven patients were considered as evaluable according to ORR and OS. The patients' ORR was 87.5%, 100%, and 50% in the F/F, V/F, and V/V allele groups, respectively. We did not establish any statistically significant differences among the 3 alleles groups in respect to ORR (p=0.93). The OS within 2 years in the F/F, V/F, and V/V allele groups was 62.5%, 100%, and 100%, respectively. The OS in the F/F allele group was found to be lower than in the other 2 allele groups (p=0.01).The distribution of gene polymorphisms in our study group was similar to those of previous studies. While ORR was similar between the groups, our results highlight a lower OS in F/F patients compared to other allele groups of FcγRIIIA.Amaç: Diffüz büyük B hücreli non-Hodgkin lenfomada (DLBCL) kür sağlayıcı tedavi yaklaşımı rituximab çağında olmamıza rağmen tartışmalı bir konudur. Bu çalışmanın amacı R-CHOP (siklofosfamid, doksorubisin, vinkristin ve prednizon) rejimi alan DLBCL hastalarında FcγRIIIA gen polimorfizminin dağılımını incelemekti. Ayrıca FcγRIIIA gen polimorfizminin tüm yanıt oranları (ORR) ve tüm yaşam (OS) üzerine olan etkisini araştırmaktı. Gereç ve Yöntemler: Türkiye’nin Ege Bölgesi’ndeki üç merkezden yeni tanı almış CD-20 pozitif DLBCL hastaları çalışmaya dahil edildi. FcγRIIIA’daki tek gen polimorfizmi gerçek zamanlı-PCR ile incelendi. Tedaviye yanıt, planlanmış olan protokolün ortasında ve sonunda değerlendirildi. İki yıllık takip süresince her üç ayda bir hastalığın hem klinik, hem de radyolojik durumu ele alındı. Bulgular: Çalışmaya dahil edilen 36 hastada, FcγRIIIA’nın F/F, V/F ve V/V alellerinin dağılımı sırasıyla %25, %50 ve %25’ti. ORR ve OS verilerine göre 27 hasta değerlendirilebilir olarak kabul edildi. Hastaların ORR değerleri F/F, V/F ve V/V alel gruplarına göre sırasıyla %87,5; %100 ve %50 olarak hesaplandı. Hastaların ORR değerleri açısından üç alel grubu arasında istatistiksel olarak anlamlı fark saptanmadı (p=0,93). F/F, V/F ve V/V gruplarında iki yıllık OS %62,5, %100 ve %100 bulundu. F/F alel grubunun OS’si diğer iki alel grubundakinden daha düşük bulunmuştur (p=0,01). Sonuç: Gen polimorfizmi dağılımı sonuçlarımız önceki çalışmalarda bulunanlarla benzerdir. Gruplar arasında ORR değerleri arasında fark yokken, sonuçlarımız F/F hastalarının FcγRIIIA’nın diğer allel gruplarına göre daha kısa bir OS değerine sahip olduğunu göstermektedir.
- Published
- 2015
17. Alpha-Thalassemia Mutations in Adana Province, Southern Turkey: Genotype-Phenotype Correlation
- Author
-
Nurhilal Büyükkurt, Huseyin Aslan, Ozge Ozalp Yuregir, Sevcan Tug Bozdogan, Tomasz Gambin, and Zeynep Canan Özdemir
- Subjects
Genetics ,medicine.medical_specialty ,Mutation ,education.field_of_study ,Hematology ,Anemia ,Phenotype-genotype correlation ,Microcytosis ,Population ,Alpha-thalassemia ,Biology ,medicine.disease ,medicine.disease_cause ,Internal medicine ,Genotype ,medicine ,Original Article ,education ,Gene - Abstract
To look over the distribution of the mutations in a large series from Adana province, Southern Turkey, and determine the genotype-phenotype correlation of the frequent mutations. Among the 2500 individuals with mild or moderate anemia, microcytosis, and normal iron levels that were referred to our Genetic Diagnosis Center, a population consisting of 539 individuals were included in the study and tested for alpha-thalassemia mutations by using reverse dot blot hybridization technique. Twelve different mutations were detected in 539 patients. Among the 12 different mutations found, the most frequent mutations were the -alpha(3.7) (63.3 %), --(MED) (11.7 %), --(20.5) (10.7 %), alpha 2(IVS1(-5nt)) (3.9 %), and alpha 2(polyA-2) (3.5 %). The most frequent genotypes were -alpha(3.7)/alpha alpha (35.8 %), -alpha(3.7)/-alpha(3.7)(18.9 %), -(20.5)/alpha alpha (11.5 %), and --(MED)/alpha alpha (10.4 %), respectively. There were statistically significant differences in hematological findings between -alpha(3.7)/-alpha(3.7) and --(MED)/alpha alpha, even though both have two mutated genes in the genotype. Our results show that alpha-thalassemia mutations are highly heterogeneous as well as deletional and -alpha(3.7) single gene deletion is particularly prevalent at Adana province in agreement to other studies from Turkey.
- Published
- 2014
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.